Management of inadequate response in major depressive disorder and new treatment options

被引:0
作者
Karamustafahoglu, Oguz [1 ]
Yavuz, Burcu Goksan [1 ]
机构
[1] Sisli Etfal Egitirn Arastirma Hastanesi, Psikiyatri Klin, TR-34377 Istanbul, Turkey
来源
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY | 2011年 / 21卷
关键词
Quetiapine XR; depression; anxiety; adjunctive therapy; monotherapy; EXTENDED-RELEASE QUETIAPINE; SEROTONIN REUPTAKE INHIBITORS; A-DOUBLE-BLIND; FUMARATE MONOTHERAPY; ADJUNCTIVE THERAPY; BIPOLAR-I; EFFICACY; MULTICENTER; ANTIDEPRESSANT; ARIPIPRAZOLE;
D O I
10.1080/10177833.2011.11790745
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Purpose of this study is to review the studies investigating the efficacy and tolerability of extended-release quetiapine (quetiapine XR) as adjunctive therapy and monotherapy in major depressive disorder. Method: Nine articles were reviewed that were reached after the search in Medline/pubmed search engine by using "quetiapine XR", "depression", "anxiety" key words. The search was done in March 2011. The reviewed articles were published between 2009 and 2011. Results: In studies that investigate the efficacy of quetiapine XR as adjunctive therapy remission rates were found between 31%-42.5%. Remission rates were found between 20.8%-34.7% in studies that investigate the efficacy of quetiapine XR monotherapy. Studies showed that MADRS total scores were significantly reduced compared to placebo at week 1. Satistically significant improvements were seen in HAM-D total, HAM-A total, and HAM-A psychic anxiety cluster scores. Besides reducing depressive symptoms, quetiapine XR is also significantly effective in anxiety symptoms compared to placebo. Conclusion: Because of significant effectiveness, high tolerability rates, quetiapine XR emerges as a new treatment option in patients with major depressive disorder with an inadequate response, treatment resistance, concomitant anxiety symptoms. Moreover significant improvement in inner tension, reduced sleep, pessimistic thoughts as early as week 1 is clinically important
引用
收藏
页码:S20 / S25
页数:6
相关论文
共 35 条
  • [1] Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability
    Anderson, IM
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2000, 58 (01) : 19 - 36
  • [2] [Anonymous], DEPR
  • [3] Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study
    Bandelow, Borwin
    Chouinard, Guy
    Bobes, Julio
    Ahokas, Antti
    Eggens, Ivan
    Liu, Sherry
    Eriksson, Hans
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (03) : 305 - 320
  • [4] A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder
    Bauer, Michael
    El-Khalili, Nizar
    Datto, Catherine
    Szamosi, Johan
    Eriksson, Hans
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2010, 127 (1-3) : 19 - 30
  • [5] Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study
    Bauer, Michael
    Pretorius, Herman W.
    Constant, Eric L.
    Earley, Willie R.
    Szamosi, Johan
    Brecher, Martin
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (04) : 540 - 549
  • [6] The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study
    Berman, Robert M.
    Marcus, Ronald N.
    Swanink, Rene
    McQuade, Robert D.
    Carson, William H.
    Corey-Lisle, Patricia K.
    Khan, Arif
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (06) : 843 - 853
  • [7] Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
    Berman, Robert M.
    Fava, Maurizio
    Thase, Michael E.
    Trivedi, Madhukar H.
    Swanink, Rene
    McQuade, Robert D.
    Carson, William H.
    Adson, David
    Taylor, Leslie
    Hazel, James
    Marcus, Ronald N.
    [J]. CNS SPECTRUMS, 2009, 14 (04) : 197 - 206
  • [8] Bird D., 2002, Klinik Psikofarmakoloji Bulteni/Bulletin of Clinical Psychopharmacology, V12, P92
  • [9] Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study
    Bortnick, Brian
    El-Khalili, Nizar
    Banov, Michael
    Adson, David
    Datto, Catherine
    Raines, Shane
    Earley, Willie
    Eriksson, Hans
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2011, 128 (1-2) : 83 - 94
  • [10] Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials
    Buckley, PF
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) : 1357 - 1363